clinical trial · NCT07502872
TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
Brown University·phase2·not yet recruiting·n = 30
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaLymphomaLymphoma, B-CellTafasitamabPolatuzumab vedotinGlofitamabObinutuzumab
brief summary
This is a single-center, phase 2, open-label clinical trial of a novel combination of polatuzumab vedotin, glofitamab, and tafasitamab (TPG) as first-line treatment of patients with diffuse large B cell lymphoma (DLBCL) or high-grade B cell lymphoma (HGBL).
started
May 1, 2026
primary completion
Dec 1, 2029
completion
Dec 1, 2029
last updated
Mar 31, 2026
official title
TPG: a Phase 2 Trial of Polatuzumab Vedotin, Glofitamab, and Tafasitamab as Chemotherapy-sparing First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol